Adrenomyeloneuropathy with cerebral involvement due to a novel frameshift variant in ABCD1 gene

Article information

. 2021;23(1):61-64
Publication date (electronic) : 2021 April 29
doi : https://doi.org/10.14253/acn.2021.23.1.61
1Department of Neurology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
2Graduate School of Medical Science and Engineering, Korea Advanced Institute of Science and Technology, Daejeon, Korea
Correspondence to Kwang-Kuk Kim Department of Neurology, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul 05505, Korea Tel: +82-2-3010-3444 Fax: +82-2-474-4691 E-mail: kkkim@amc.seoul.kr
*

Hye Weon Kim and Hyunjin Kim equally contributed to this study.

Received 2021 January 19; Revised 2021 March 7; Accepted 2021 March 10.

Abstract

Adrenoleukodystrophy (ALD) is the most common peroxisomal disorder caused by mutations in the gene, ABCD1, causing abnormal accumulation of very-long-chain fatty acids in the nervous system and adrenal glands. There are various clinical manifestations of ALD. Here we report a 47-year-old male with adrenomyeloneuropathy with cerebral involvement who exhibited progressive gait disturbance and cognitive impairment. A novel frameshift variant (c.95del [p.Val32Alafs*36]) in exon 1 of ABCD1 was identified. This report provides additional information regarding the various clinical characteristics of ALD.

Adrenoleukodystrophy (ALD) is the most common peroxisomal disorder caused by mutations in the ATP-binding cassette protein subfamily D1 gene (ABCD1), which is located on the X chromosome. ABCD1 encodes for the peroxisomal membrane transporter ALD protein (ALDP), which is involved in the degradation of very-long-chain fatty acids (VLCFAs).1 Defects in ALDP result in abnormal accumulation of VLCFA in the nervous system, adrenal glands, and testes, causing various clinical manifestations.2 ALD is traditionally categorized into four phenotypes: cerebral ALD, adrenomyeloneuropathy (AMN), Addison’s disease only, and asymptomatic carriers.3 AMN usually manifests between the ages of 20 and 50 years with progressive noninflammatory axonopathy that primarily involves the spinal cord and peripheral nerves, leading to spastic paraparesis and sensory ataxia. Furthermore, inflammatory cerebral demyelination occurs in up to 60% of male patients.4 We report here a patient with AMN with cerebral involvement due to a novel frameshift variant in exon 1 of ABCD1.

CASE

A 47-year-old male visited the outpatient clinic complaining of cognitive impairment, which had deteriorated over a period of 3 years. During his late 20s, the patient suffered from back pain and gait disturbance, which had slowly progressed. By his late 30s, he noticed a darkening of his skin and was taking sildenafil to treat erectile dysfunction. Over the past 3 years he experienced occasional falls due to a deterioration of his gait disturbance and had difficulties making appropriate decisions, finding directions, and making calculations. He reported no concurrent disease or relevant past medical history, including hypertension and diabetes. The patient did not have any history of intoxication or infection. However, he had a family history of cognitive impairment and gait disturbance, suggesting X-linked recessive inheritance (Fig. 1).

Fig. 1.

Pedigree of the patient. The arrow indicates the proband.

A neurological examination revealed an alert mental status, although disorientation for place was observed. He had a decreased Mini Mental State Examination score of 20. Cortical dysfunction was observed in multiple domains, including perseveration, ideomotor apraxia, acalculia, and finger agnosia. Cranial nerve examinations did not reveal any significant abnormalities. Motor power was intact, while deep tendon reflexes were hyperactive with positive bilateral Babinski and Hoffman signs. Bilateral limb ataxia was observed in the arms and legs, along with severely impaired position and vibration sense of lower extremities. His gait was wide-based, spastic, and ataxic.

The baseline adrenocorticotropic hormone (ACTH) concentration measured in the morning was elevated at 161 pg/mL (reference 7-63 pg/mL), but the result of a rapid ACTH stimulation test was within normal limits (baseline serum cortisol level, 19 μg/dL; serum cortisol level at 60 minutes after stimulation, 27.4 μg/dL). Plasma VLCFA levels of C26:0, and C24:0/C22:0 and C26:0/C22:0 ratios were increased, at 3.8 μmol/L (reference ≤ 1.3 μmol/L), 2.0 (reference ≤ 1.39), and 0.093 (reference ≤ 0.023), respectively. Motor evoked potentials and posterior tibial somatosensory evoked potentials demonstrated central conduction delay, but a nerve conduction study did not reveal definitive electrophysiological evidence of neuropathy. Brain magnetic resonance imaging revealed increased signal intensities on T2-weighted images in the bilateral corticospinal tracts, the frontoparietooccipital subcortex, and the splenium of the corpus callosum (Fig. 2). Sanger sequencing of all 10 exons and flanking intron regions of ABCD1 (NM_000033.4) revealed a novel frameshift variant (c.95del [p.Val32Alafs*36]) in exon 1 (Fig. 3). This variant, which has not been reported previously in either ClinVar (https://www.ncbi.nlm.nih.gov/clinvar/) or the ALD database (http://www.x-ald.nl/), was classified as pathogenic based on the American College of Medical Genetics and Genomics standards, as follows: 1) null variant in a gene where the loss of function is a known disease mechanism, 2) absent from controls in the 1,000 Genomes Project (https://www.internationalgenome.org/) and gnomAD database (https://gnomad.broadinstitute.org/), and 3) in-silico analyses using MutationTaster (http://www.mutationtaster.org/) and LoFtool (https://asia.ensembl.org/Tools/VEP) supporting a deleterious effect.

Fig. 2.

Brain magnetic resonance imaging of the patient. Axial fluid-attenuated inversion recovery images showing increased signal intensities in the bilateral corticospinal tract (A), the splenium of the corpus callosum and the bilateral occipital subcortex (B), and the bilateral frontoparietal subcortex (C).

Fig. 3.

Sanger sequencing chromatogram of the patient. Sequencing analysis revealed a deletion in exon 1 of ABCD1 (arrow, c.95del), which is a frameshift variant that causes premature termination of translation (p.Val32Alafs*36).

DISCUSSION

We report here a case of AMN with cerebral involvement due to a novel frameshift variant that has not been reported previously. The phenotype of ALD is heterogeneous, but can be classified mainly as either cerebral ALD or AMN. The pathologies of cerebral ALD and AMN are fundamentally different; while the pathology of cerebral ALD is considered to be inflammatory demyelination, that of AMN is thought to be chronic neurodegeneration.5 In addition, the absence of a genotype-phenotype correlation has been demonstrated by several case series.4 These data support the hypothesis that Fig. 1. Pedigree of the patient. The arrow indicates the proband. a primary defect in ABCD1 results in AMN, but that additional environmental triggers or genetic modifiers are required to initiate cerebral demyelination.4

In a previous report of 12 Korean AMN patients that confirmed complex clinical phenotypes, 2 patients harbored a frameshift variant that manifested as the spinocerebellar phenotype.6 By contrast, the frameshift variant in our case manifested as AMN with cerebral involvement.6 In the aforementioned study, two patients were classified as having AMN with cerebral demyelination; one of these patients had a missense variant and the other had a deletion variant.6 In addition, it has been reported that adult cerebral ALD tends to involve the frontal rather than the parietooccipital area of the brain,7 but our adult-onset case manifested predominately with parietooccipital dysfunction. The findings of this case also support the lack of a genotype–phenotype correlation in ALD.

Treatments for ALD differ according to the targeted symptoms. Glucocorticoid supplementation is needed for adrenal insufficiency, and symptomatic management with supportive care is required for myelopathy. For cerebral ALD, allogeneic hematopoietic stem cell transplantation (HSCT) has been shown to halt disease progression in both childhood and adulthood cases.8 However, allogeneic HSCT has several risks, including treatment-related mortality, graft failure, graft-versus-host disease, and opportunistic infections.8 In 2017, a gene-therapy based approach was developed for the treatment of childhood ALD: autologous HSCT using autologous CD34+ stem cells corrected ex vivo with the lentiviral vector carrying wild-type ABCD1. This approach conferred long-term disease stabilization and had a reasonable safety profile.9 A gene therapy is also under development for AMN. Gong et al.10 found that delivery of an adenoviral vector containing human ABCD1 to mouse central nervous system cells resulted in localization of ALDP to the peroxisome, with a subsequent decrease in VLCFAs, both in vitro and in a mouse model of X-linked ALD.

Given the substantial progress in therapeutic interventions, the importance of accurate diagnosis is increasing. Clinicians should be aware of the heterogeneous clinical presentations and the lack of a genotype-phenotype correlation in ALD.

Notes

Author Contributions

K.-K.K. contributed to study concept and design. All authors contributed to data acquisition and analysis. H.W.K. and H.K. drafted a significant proportion of the manuscript and figures. D.J., K.C., E.-J.L., Y.-M.L., and K.-K.K. revised the manuscript critically for important intellectual content. All authors read and approved the final manuscript.

Conflicts of Interest

The authors declare that they have no conflicts of interest relevant to this article.

References

1. Mosser J, Douar AM, Sarde CO, Kioschis P, Feil R, Moser H, et al. Putative X-linked adrenoleukodystrophy gene shares unexpected homology with ABC transporters. Nature 1993;361:726–730.
2. Boehm CD, Cutting GR, Lachtermacher MB, Moser HW, Chong SS. Accurate DNA-based diagnostic and carrier testing for X-linked adrenoleukodystrophy. Mol Genet Metab 1999;66:128–136.
3. Pavlakis SG. New insights into adrenoleukodystrophy. Eur J Paediatr Neurol 2017;21:597.
4. Kemp S, Huffnagel IC, Linthorst GE, Wanders RJ, Engelen M. Adrenoleukodystrophy-neuroendocrine pathogenesis and redefinition of natural history. Nat Rev Endocrinol 2016;12:606–615.
5. Berger J, Forss-Petter S, Eichler FS. Pathophysiology of X-linked adrenoleukodystrophy. Biochimie 2014;98:135–142.
6. Park HJ, Shin HY, Kang HC, Choi BO, Suh BC, Kim HJ, et al. Clinical and genetic aspects in twelve Korean patients with adrenomyeloneuropathy. Yonsei Med J 2014;55:676–682.
7. Vanderver A. Genetic leukoencephalopathies in adults. Continuum (Minneap Minn) 2016;22:916–942.
8. Köhler W, Curiel J, Vanderver A. Adulthood leukodystrophies. Nat Rev Neurol 2018;14:94–105.
9. Eichler F, Duncan C, Musolino PL, Orchard PJ, De Oliveira S, Thrasher AJ, et al. Hematopoietic stem-cell gene therapy for cerebral adrenoleukodystrophy. N Engl J Med 2017;377:1630–1638.
10. Gong Y, Mu D, Prabhakar S, Moser A, Musolino P, Ren J, et al. Adenoassociated virus serotype 9-mediated gene therapy for x-linked adrenoleukodystrophy. Mol Ther 2015;23:824–834.

Article information Continued

Fig. 1.

Pedigree of the patient. The arrow indicates the proband.

Fig. 2.

Brain magnetic resonance imaging of the patient. Axial fluid-attenuated inversion recovery images showing increased signal intensities in the bilateral corticospinal tract (A), the splenium of the corpus callosum and the bilateral occipital subcortex (B), and the bilateral frontoparietal subcortex (C).

Fig. 3.

Sanger sequencing chromatogram of the patient. Sequencing analysis revealed a deletion in exon 1 of ABCD1 (arrow, c.95del), which is a frameshift variant that causes premature termination of translation (p.Val32Alafs*36).